Yamanouchi Will Promote Vesicare With 150 Specialty Sales Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA clears Vesicare for the treatment of overactive bladder. Yamanouchi and co-promotion partner GlaxoSmithKline will launch solifenacin in January 2005, with GSK sales reps handling primary care duties and Yamanouchi reps detailing to urologist and ob/gyns.
You may also be interested in...
The Quality Lowdown: Corporate Culture And Site Complexity Can Pose Challenges
Quality and the measure of a firm: Toyobo’s particulates and resins, Galenicko’s sanitation, Breckenridge’s product chemistry and Fujifilm’s cross-contamination risk.
Novartis' Enablex For Overactive Bladder Clears FDA
Enablex will enter a crowded overactive bladder market in early 2005 that includes two recent entrants, Yamanouchi/GlaxoSmithKline's Vesicare and Indevus/Pliva's Sanctura. Novartis may emphasize darifenacin's "unique" action on the M3 receptor to distinguish it from competitors.
Novartis' Enablex For Overactive Bladder Clears FDA
Enablex will enter a crowded overactive bladder market in early 2005 that includes two recent entrants, Yamanouchi/GlaxoSmithKline's Vesicare and Indevus/Pliva's Sanctura. Novartis may emphasize darifenacin's "unique" action on the M3 receptor to distinguish it from competitors.